乐和彩开户

Oncology

identifying & reducing barriers to oncology clinical research at site level

recent developments in cancer immunotherapy illustrate virtually unprecedented clinical benefit in some advanced cancer patients, and the potential for cure seems tangible. in line with transforming patient care, we have also already begun to transform drug development.

乐和彩开户icon conducts clinical studies in both solid and haematological tumours including breast, lung, gastric, hcc, prostate, multiple myeloma, aml, lymphoma and leukaemia.

ICON services your oncology trial can benefit from include:

Transforming patient outcomes

乐和彩开户the explosion of information about the genetic aberrations underlying cancer has led to several changes in the paradigm of how we develop drugs for this disease. we believe that transformation of the outcomes for patients with cancer will require detailed understanding of these genetic aberrations in each patient’s cancer at diagnosis.

targeted therapies, novel immunotherapies and the ability to combine these agents together successfully will be important in the development of effective and tolerable treatment regimens.

with almost 40% of our projects focused in oncology, our project managers and clinical teams have a deep experience in the challenges of clinical development in this area.

Two thirds of oncology studies are in early phase

Two thirds of oncology studies are in early phase

Operationalised alternative study designs, such as the nCRM

Operationalised alternative study designs, such as the nCRM

Managing some of the largest global phase III registration studies

Managing some of the largest global phase III registration studies
乐优彩票天天红单下载 乐优彩票登入,备用,官方网址 乐优彩票网址是多少 乐优炫彩app 乐优炫彩app下载 乐优炫彩app天天红单 乐信pc下载 乐其彩票网站 乐优炫彩天天红单 乐优炫彩官网